Logo image of SNDL

SNDL INC (SNDL) Stock Fundamental Analysis

NASDAQ:SNDL - Nasdaq - CA83307B1013 - Common Stock - Currency: USD

1.39  -0.02 (-1.42%)

After market: 1.3982 +0.01 (+0.59%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SNDL. SNDL was compared to 198 industry peers in the Pharmaceuticals industry. While SNDL seems to be doing ok healthwise, there are quite some concerns on its profitability. SNDL does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SNDL had negative earnings in the past year.
In the past year SNDL had a positive cash flow from operations.
In the past 5 years SNDL always reported negative net income.
SNDL had negative operating cash flow in 4 of the past 5 years.
SNDL Yearly Net Income VS EBIT VS OCF VS FCFSNDL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

SNDL has a Return On Assets of -7.03%. This is in the better half of the industry: SNDL outperforms 71.72% of its industry peers.
SNDL's Return On Equity of -8.36% is fine compared to the rest of the industry. SNDL outperforms 77.27% of its industry peers.
Industry RankSector Rank
ROA -7.03%
ROE -8.36%
ROIC N/A
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
SNDL Yearly ROA, ROE, ROICSNDL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

SNDL's Gross Margin of 26.11% is in line compared to the rest of the industry. SNDL outperforms 53.03% of its industry peers.
SNDL's Gross Margin has been stable in the last couple of years.
SNDL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 26.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
SNDL Yearly Profit, Operating, Gross MarginsSNDL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNDL has about the same amount of shares outstanding.
The number of shares outstanding for SNDL has been increased compared to 5 years ago.
The debt/assets ratio for SNDL has been reduced compared to a year ago.
SNDL Yearly Shares OutstandingSNDL Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
SNDL Yearly Total Debt VS Total AssetsSNDL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

SNDL has an Altman-Z score of 0.95. This is a bad value and indicates that SNDL is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of SNDL (0.95) is better than 62.12% of its industry peers.
The Debt to FCF ratio of SNDL is 3.47, which is a good value as it means it would take SNDL, 3.47 years of fcf income to pay off all of its debts.
SNDL has a better Debt to FCF ratio (3.47) than 88.38% of its industry peers.
SNDL has a Debt/Equity ratio of 0.10. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of SNDL (0.10) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 3.47
Altman-Z 0.95
ROIC/WACCN/A
WACC8.27%
SNDL Yearly LT Debt VS Equity VS FCFSNDL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

SNDL has a Current Ratio of 5.10. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
SNDL has a better Current ratio (5.10) than 74.24% of its industry peers.
SNDL has a Quick Ratio of 3.67. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
SNDL has a Quick ratio of 3.67. This is in the better half of the industry: SNDL outperforms 63.64% of its industry peers.
Industry RankSector Rank
Current Ratio 5.1
Quick Ratio 3.67
SNDL Yearly Current Assets VS Current LiabilitesSNDL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 85.64% over the past year.
The Revenue has decreased by -7.88% in the past year.
EPS 1Y (TTM)85.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-7.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-0.22%

3.2 Future

SNDL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.81% yearly.
SNDL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 80.96% yearly.
EPS Next Y40.31%
EPS Next 2Y33.31%
EPS Next 3Y23.32%
EPS Next 5Y13.81%
Revenue Next Year1181.89%
Revenue Next 2Y311.6%
Revenue Next 3Y157.37%
Revenue Next 5Y80.96%

3.3 Evolution

SNDL Yearly Revenue VS EstimatesSNDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
SNDL Yearly EPS VS EstimatesSNDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SNDL. In the last year negative earnings were reported.
Also next year SNDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDL Price Earnings VS Forward Price EarningsSNDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SNDL is valued a bit cheaper than the industry average as 79.80% of the companies are valued more expensively.
89.39% of the companies in the same industry are more expensive than SNDL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 11.27
EV/EBITDA 16.17
SNDL Per share dataSNDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

SNDL's earnings are expected to grow with 23.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.31%
EPS Next 3Y23.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SNDL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SNDL INC

NASDAQ:SNDL (5/2/2025, 8:00:02 PM)

After market: 1.3982 +0.01 (+0.59%)

1.39

-0.02 (-1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-30 2025-07-30
Inst Owners16.37%
Inst Owner Change-0.08%
Ins Owners0.33%
Ins Owner ChangeN/A
Market Cap357.63M
Analysts82.5
Price Target3.57 (156.83%)
Short Float %1.39%
Short Ratio2.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)153.92%
Min EPS beat(2)-37.25%
Max EPS beat(2)345.1%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.88%
Min Revenue beat(2)-0.07%
Max Revenue beat(2)1.83%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.69%
PT rev (3m)7.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-175%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.32%
Revenue NY rev (3m)1.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.54
P/FCF 11.27
P/OCF 9.01
P/B 0.44
P/tB 0.52
EV/EBITDA 16.17
EPS(TTM)-0.98
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)0.12
FCFY8.88%
OCF(TTM)0.15
OCFY11.1%
SpS2.59
BVpS3.19
TBVpS2.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.03%
ROE -8.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 26.11%
FCFM 4.77%
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score8
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF 3.47
Debt/EBITDA 5.1
Cap/Depr 19.43%
Cap/Sales 1.2%
Interest Coverage N/A
Cash Conversion 237.09%
Profit Quality N/A
Current Ratio 5.1
Quick Ratio 3.67
Altman-Z 0.95
F-Score8
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y40.31%
EPS Next 2Y33.31%
EPS Next 3Y23.32%
EPS Next 5Y13.81%
Revenue 1Y (TTM)-7.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-0.22%
Revenue Next Year1181.89%
Revenue Next 2Y311.6%
Revenue Next 3Y157.37%
Revenue Next 5Y80.96%
EBIT growth 1Y45.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year108.49%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y278.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y429.85%
OCF growth 3YN/A
OCF growth 5YN/A